CAS NO: | 249503-25-1 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viralRNA-dependent RNA polymerase (RdRp)activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV,SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM[1][2][3]. | ||||||||||||||||
IC50& Target | RdRp | ||||||||||||||||
体外研究 (In Vitro) | Cellular kinases phosphorylate Galidesivir (BCX4430) to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination[1]. | ||||||||||||||||
体内研究 (In Vivo) | Galidesivir (BCX4430) is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir has demonstrated pronounced efficacy[1].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 265.27 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C11H15N5O3 | ||||||||||||||||
CAS 号 | 249503-25-1 | ||||||||||||||||
中文名称 | 加利司韦;加利地韦 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: H2O : 1.53 mg/mL(5.77 mM;Need ultrasonic and warming) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |